lipophosphonoglycan

macromolecule accounting for approx 31% of mass of plasma membrane of Acanthamoeba castellanii; consists of neutral sugars, amino sugars, aminophosphonates and long chain fatty acids; present also in Entamoeba histolytica and Leishmania major

Also Known As:

Networked: 55 relevant articles (5 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Beverley, Stephen M: 5 articles (01/2021 - 08/2003)
2.	Turco, Salvatore J: 5 articles (10/2004 - 07/2002)
3.	Späth, Gerald F: 4 articles (04/2009 - 08/2003)
4.	Soares, Rodrigo P: 3 articles (07/2022 - 05/2012)
5.	Bagirova, Melahat: 3 articles (01/2021 - 06/2013)
6.	Abamor, Emrah Sefik: 2 articles (01/2021 - 09/2017)
7.	Soares, Rodrigo Pedro: 2 articles (01/2021 - 01/2019)
8.	Akdeste, Zeynep: 2 articles (09/2017 - 06/2013)
9.	Allahverdiyev, Adil M: 2 articles (09/2017 - 06/2013)
10.	Cakir Koc, Rabia: 2 articles (09/2017 - 06/2013)

Related Diseases

1.	Visceral Leishmaniasis (Kala Azar) 07/15/1991 - "We investigated the role played by the lipophosphoglycan (LPG) in determining the reactivity of kala-azar serum with the surface of Leishmania donovani promastigotes. " 07/15/1991 - "Lipophosphoglycan masks recognition of the Leishmania donovani promastigote surface by human kala-azar serum." 06/01/1994 - "II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients." 02/01/1991 - "Peripheral blood mononuclear cells (PBMC) from cured Kala-Azar patients proliferated and produced Interferon-gamma in vitro in response to lipophosphoglycan (LPG) isolated from Leishmania major. " 01/01/2021 - "Nano-co-delivery of lipophosphoglycan with soluble and autoclaved leishmania antigens into PLGA nanoparticles: Evaluation of in vitro and in vivo immunostimulatory effects against visceral leishmaniasis."
2.	Infections 01/01/2017 - "NKT cells have been associated with protection against Leishmania donovani, yet their role in infections with Leishmania mexicana has not been addressed, nor has the activation pathway been defined after stimulation with Leishmania mexicana lipophosphoglycan (LPG). " 08/01/1991 - "Previous studies using immunostaining and light microscopy demonstrated expression of Leishmania major lipophosphoglycan (LPG) on parasites developing in the sandfly gut from 2 days post infection. " 07/01/2017 - "A Non-pathogenic Recombinant Leishmania Expressing Lipophosphoglycan 3 Against Experimental Infection with Leishmania infantum." 10/06/2016 - "Furthermore, it appears that lipophosphoglycan (LPG) is not the major mediator of TLR2 activation during infection with L. " 05/01/2012 - "chagasi infection or lipophosphoglycan isolated from promastigotes triggered HO-1 production by murine macrophages. "
3.	Cutaneous Leishmaniasis 03/30/2007 - "Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan." 11/01/1989 - "We have previously reported that a Leishmania major lipophosphoglycan (LPG), given with killed Corynebacterium parvum as an adjuvant, can vaccinate mice against cutaneous leishmaniasis. " 10/06/2016 - "Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan." 03/30/2007 - "Here, the role played by lipophosphoglycan (LPG) as the key disease-promoting component of intramuscular (i.m.) LaAg and its usefulness as a defined intranasal vaccine was investigated in murine cutaneous leishmaniasis. " 10/01/1993 - "The Leishmania protein LPGAP which is co-isolated with lipophosphoglycan is a specific activator of T cells from individuals who have recovered from American leishmaniasis. "
4.	Amebiasis (Amoebiasis) 11/03/1997 - "Protection against invasive amebiasis by a single monoclonal antibody directed against a lipophosphoglycan antigen localized on the surface of Entamoeba histolytica." 03/24/2000 - "Trophozoites of the parasitic protozoa, Entamoeba histolytica, synthesize a cell surface lipoglycoconjugate, termed lipophosphoglycan, which is thought to be an important virulence factor and potential vaccine candidate against invasive amebiasis. " 09/01/1995 - "Human immune sera from amoebiasis patients and a polyclonal antibody against HM-1:IMSS lipophosphoglycan both recognized Rahman glycoconjugate. "
5.	Leishmaniasis 04/01/1992 - "In a cross-sectional house-to-house study in a leishmaniasis-endemic area in Kenya, the cellular and humoral immune response to Leishmania lipophosphoglycan (LPG) was determined. " 05/17/2002 - "Lipophosphoglycan is a major surface molecule of Leishmania, protozoa parasites, which are the causative agents of leishmaniasis, a disease that annually afflicts millions of people worldwide. " 07/01/2022 - "Lipophosphoglycan (LPG) is the Leishmania multifunctional virulence factor during host-parasite interaction, whose polymorphisms are involved in the immunopathology of leishmaniasis. " 01/01/2019 - "Leishmania infantum-derived lipophosphoglycan as an antigen in the accurate serodiagnosis of canine leishmaniasis." 06/03/2013 - "Therefore, we aimed to develop a potential vaccine candidate against leishmaniasis by covalently conjugating PAA with an immunologically vital molecule of lipophosphoglycan (LPG) found in Leishmania parasites. "

Related Drugs and Biologics

1.	Antigens
2.	Proteins (Proteins, Gene)
3.	Monoclonal Antibodies
4.	Interferon-gamma (Interferon, gamma)
5.	Vaccines
6.	Glycoproteins (Glycoprotein)
7.	Heat-Shock Proteins (Heat-Shock Protein)
8.	Fucosyltransferases
9.	Glycoconjugates
10.	Virulence Factors (Pathogenicity Factors)